Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988233 | 0.85 | HPGDS (0.65) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL219909 | 0.85 | HDAC6 (0.59) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL3088708 | 0.85 | HDAC6 (0.71) | HDAC6HDAC1HDAC4 | |
| SCHEMBL5209156 | 0.83 | SRD5A2 (0.62) | MEN1KMT2AHDAC6HDAC1ALDH1A1 | |
| SCHEMBL6264067 | 0.83 | RAB9A (0.64) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL422509 | 0.82 | RAB9A (0.72) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL27773425 | 0.81 | HDAC6 (0.48) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL3308044 | 0.81 | HDAC6 (0.46) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL3308038 | 0.81 | HDAC6 (0.46) | RAB9AMEN1KMT2APOLBHDAC6 | |
| SCHEMBL3308049 | 0.81 | HDAC6 (0.46) | RAB9AMEN1KMT2APOLBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| EP-1401825-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | Shire Biochem Inc. (CA) | 2004-03-31 | — | — | EP | claimed |
| WO-2002100851-A2 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | SHIRE BIOCHEM INC. (CA) | 2002-12-19 | — | — | WO | claimed |
| WO-2015069011-A1 | NOVEL COMPOUND, METHOD FOR PREPARATION THEREOF, AND ANTIFUNGAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-14 | — | — | WO | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| US-7067509-B2 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005103039-A1 | 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005030206-A1 | ARYL-1,3-AZOLE DERIVATIVES AND METHODS FOR INHIBITING HEPARNASE ACTIVITY | IMCLONE SYSTEMS INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080411-A2 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-0259972-B1 | HETEROCYCLIC PROPENE AMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | LILLY INDUSTRIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| US-4983619-A | Leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1991-01-08 | — | — | US | disclosed |
| EP-0259972-A2 | Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259931-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | RAB9A 1225/4885MEN1 658/4885KMT2A 1082/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | RAB9A 3129/4885MEN1 3552/4885KMT2A 3983/4885 |
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | RAB9A 1618/4885MEN1 401/4885KMT2A 1273/4885 |
| US-20050256124-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | RAB9A 2176/4885MEN1 1006/4885KMT2A 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.